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Background: Surgical resection is considered the standard therapy in the treatment of liver metastases from colorectal
cancer (CRCLM); however, most patients experience tumor recurrence after curative hepatic resection. The objective
was to determine potential prognostic factors for tumor recurrence after an initial hepatectomy for CRCLM.
Methods: A study population of 101 patients who had undergone a first curative hepatectomy for CRCLM was
retrospectively analyzed. Selected biological tumor markers, and clinical and pathological features were then tested
by Cox regression.
Results: Synchronous liver metastases occurred in 38 patients (37.6%) and 63 patients (62.3%) presented with
metachronous liver metastases. In a median follow-up time of 68 months, recurrence was observed in 64 patients
(63.3%). The 5-year cumulative risk of recurrence was 56.7%. The median survival after recurrence was 24.5 months
(range 1 to 41 months) and 5-year cumulative overall survival was 31.8%. Of all variables tested by Cox regression,
intra- and extrahepatic resectable disease, CEA levels ≥50 ng/mL and bilobar liver disease remained significant as
predictors of recurrence in the multivariate analysis.
Conclusions: Independent risk factors for recurrence after an initial hepatectomy for CRCLM, such as intra- and
extrahepatic resectable disease, CEA levels ≥50 ng/mL and bilobar liver disease, can eventually help in making
decisions in this very complex scenario.
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Despite recent improvements in the diagnosis and man-
agement of colorectal cancer, many cases are still diagnosed
in advanced stages or relapse after curative treatment, with
liver, lung or peritoneal metastases. For liver metastases, in
many situations a resection is recommended, since it is
currently the most effective therapy alone [1-12]. However,
50% to 75% of patients experience tumor recurrence after
the first liver resection, and for only 20% to 30% of patients
is the initial hepatectomy a curative treatment [4-6,13].
For a post-hepatectomy recurrence, the treatment strategy
may be very complex, and invariably includes systemic
treatment possibly combined with surgical resection [14].* Correspondence: lcbredt@gmail.com
Department of Abdominal Surgery, Hepatobiliary Section, Cancer
Hospital-UOPECCAN, Cascavel, PR 85812-270, Brazil
© 2014 Bredt and Rachid; licensee BioMed Ce
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.The identification of potential preoperative predictors
of future recurrence in a candidate for liver resection for
colorectal cancer liver metastases (CRCLM) is of great
importance, because it may preclude or strongly indicate
a liver resection, possibly combined with resection of
other organs. The same is true for eventual intra-operative
or pathological predictors, as long as we do not neglect
unexpected resectable extrahepatic disease, unexpected
macrovascular invasion, eventual resections within the R0
limit with narrow macroscopic margins, and unexpected
bleeding or adherences that may interfere with the sur-
gical planning. The aim of this study is to investigate
potential clinical and pathological predictors of tumor
recurrence in resected CRCLM.ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Bredt and Rachid World Journal of Surgical Oncology 2014, 12:391 Page 2 of 8
http://www.wjso.com/content/12/1/391Methods
A retrospective analysis of an electronic database of
prospective patients undergoing hepatectomy at the hepa-
tobiliary section of an oncology referral center (a cancer
hospital) from March 2006 until March 2010 was carried
out. Only patients undergoing curative hepatectomy for
CRCLM were included; patients with unresectable disease
at initial surgical exploration were excluded. Before sur-
gery, patients signed a consent form, which contained
appropriate information about the surgical procedure
and their inclusion in the database, which was approved
by the ethics committee on human research of the
Cancer Hospital – UOPECCAN, in accordance with
the Declaration of Helsinki.
Epidemiological data and laboratory test data, including
tumor markers, tumor characteristics, treatment, and
recurrence and survival data, were analyzed to determine
prognostic factors of relapse after an initial hepatectomy
for CRCLM; re-hepatectomies were not included. Regard-
ing the timing of liver metastases, synchronous CRCLM
was defined as the simultaneous presentation of liver
metastases and primary tumor, and as metachronous if
detected after 6 months of primary tumor diagnosis.
Preoperative imaging and tumor resectability definition
CRCLM were defined as resectable if two criteria were
fulfilled: (1) oncological anticipation that the disease could
be completely resected without any residual hepatic or
extrahepatic disease and (2) it was possible to maintain an
adequate volume of the remnant liver with preserved
vascular inflow, outflow and biliary drainage. In general, at
least 25% of the total liver was considered the minimum
safe volume left after liver resection for patients with nor-
mal liver parenchyma, with or without preoperative portal
ligature or embolization.
The diagnostic capabilities available in the preoperative
staging before hepatic resection included three-dimensional
computed tomography (CT) scanning, CT angiography,
magnetic resonance imaging (MRI), CT volumetry and
positron emission tomography (PET) combining fludeoxy-
glucose-PET and helical CT.
Hepatectomy and pathological analysis
During the study, all hepatic resections were performed
with curative intent by a single oncological hepatobiliary
surgeon. The lymphadenectomy of the hepatic hilum was
not routinely performed, being reserved for cases of
suspected regional lymphatic tumor involvement. Celiac
trunk lymph nodes that were positive for malignancy in
an intraoperative frozen section, characterized the disease
as unresectable, precluding a hepatectomy. In general,
anatomical hepatectomies were performed, with the
non-anatomical resections reserved for specific situations,
such as two-stage resections. The transection of the liverparenchyma was performed with an ultrasonic cleaner,
harmonic scalpel or kelly clasia, and the smaller vessels
were ligated or coagulated by diathermy. During the
procedure, the surgical margin was carefully confirmed
by intraoperative ultrasonography to obtain free surgical
margins. Surgical mortality was defined as death occurring
within the first 30 days after the hepatectomy.
The resected specimens were studied macroscopically
and microscopically to determine tumor characteristics,
including size, number of tumors, morphology, macrovas-
cular invasion according to Kondo et al. [15], and extent
of tumor resection margins. For microscopic analysis, the
samples were fixed in 10% formaldehyde and cut into
sections of 5 mm and after cuts of 5 μm, and stained with
H & E. Two pathologists were responsible for histological
confirmation. In this study, the surgical margins were
defined as the nearest distance in millimeters between the
cut liver surface and the tumor.
Chemotherapy
The decision to begin systemic treatment in the pre- or
post-hepatectomy period was made in multidisciplinary
meetings, and eligibility included performance status of
0 to 2 according to the Eastern Cooperative Oncology
Group (ECOG) scale, the absence of systemic severe
uncompensated disease, the absence of active infection,
adequate hematologic parameters (white blood cell
(WBC) > 4.0 × 103/L, platelets > 100 × 109/L), serum cre-
atinine ≤1.2 mg/dL or creatinine clearance calculated by
Cockcroft ≥50 mL/min, total bilirubin <5.0 mg/dL, and
alanine aminotransferase and aspartate aminotransfer-
ase <100 IU/L. Regimens consisted of 5-fluorouracil (5-Fu)
alone, 5-FU/leucovorin (LV), capecitabine, FOLFOX (infu-
sional 5-FU/LV + oxaliplatin), FOLFIRI (infusional 5-FU/
LV + irinotecan) and bevacizumab.
Follow-up
Patients were followed by clinical examination, chest radi-
ography, ultrasonography, three-dimensional CT scanning
and serum carcinoembryonic antigen (CEA) every 4 to
6 months. In specific cases, MRI was used to complement
CT in the diagnosis of new liver lesions, while PET or gal-
lium scintigraphy was used for the diagnosis of systemic
recurrence. Recurrences after hepatectomy for CRCLM
were treated with surgical resection when resectable,
systemic therapy alone or combined treatments.
Statistical analysis
Baseline characteristics of the patients and tumor patho-
logical features are expressed as absolute values, mean ±
standard deviation and median (range) when appropriate.
The length of follow-up and survival are expressed as
median and ranges. Kaplan–Meier estimates of overall
survival were calculated. To assess the effect of covariates
Figure 1 The 5-year risk of tumoral recurrence (n = 101).
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estimate hazard ratios (HRs) for risk factors (categorical
and continuous variables). Recurrence was included as a
time-dependent covariate, and significant variables in the
univariate model were selected for the multivariate ana-
lysis. Cox model results are shown either as HR estimates,
together with corresponding 95% confidence intervals
(CIs), or as Wald’s test P values. According to the sample-
size calculation, there was a sufficient number of events
(recurrence) per variable for the multivariate analysis [16].
A value of P = 0.05 was considered significant. The statis-




Of the total 101 patients, 64 were men (63.3%) and 37 were
women (36.6%). The mean age at initial hepatectomy was
56.2 ± 9 years (range 36 to 79 years). The mean observation
time was 68 months (range 38 to 96 months). Among the
101 patients who underwent hepatectomy for CRCLM, 38
patients (37.6%) had synchronous liver metastases with a
primary tumor and in 63 patients (62.3%) there were meta-
chronous metastases. The CEA levels before the hepatec-
tomy were <50 ng/mL in 24 patients (23.7%) and ≥50 ng/
mL in 77 patients (76.2%). Twelve patients (11.8%) received
a hepatic resection simultaneously as a primary colorectal
tumor resection, and 89 patients (88.1%) underwent two
resection procedures. Five patients (4.9%) had resectable
lung metastasis associated with hepatic metastases. Of
these, two patients (1.9%) underwent simultaneous liver
and lung resections. Sixty-six patients (65.3%) received pre-
and post-hepatectomy systemic therapy, 12 patients (11.9%)
underwent only a before hepatectomy, and seven patients
(6.9%) underwent only an after hepatectomy.
Operative data
Regarding the type of liver resection, 80 patients under-
went anatomical resections (79.2%), 14 patients (13.8%)
underwent non-anatomical + anatomical resections (two-
stage hepatectomy), and seven patients (6.9%) underwent
non-anatomical resections. Radiofrequency ablation was
used during the liver resection in eight cases (7.9%). The
extent of hepatic resection in 35 patients (34.6%) was less
than a lobectomy and at least a lobectomy in 66 patients
(65.3%). A ligature or preoperative portal embolization
was performed in 24 cases (23.7%).
The surgical margins on the liver were ≥5 mm in
87 patients (86.1%), and in 14 patients (13.8%) they
were <5 mm. During the hepatic resection of the
parenchyma, tumors were exposed after the surface of
the liver was cut in six patients (5.9%), but were not
exposed for 95 patients (94.05%). The perioperative
mortality in this study was 2.9%.Anatomopathological characteristics of liver metastases
The average size of the largest metastasis was 3.5 ± 1.3 cm.
Of the 101 patients, 35 (34.6%) underwent a resection of
an isolated metastasis, 36 patients (35.6%) underwent re-
section of two or three tumors, and in 30 patients (29.7%),
four or more tumors were resected. In 79 patients (78.2%),
the tumor was unilobar, in 59 cases (58.4%) there were
right lobe metastases and in 20 cases (19.8%) there were
left lobe metastases. Twenty-two patients (21.7%) under-
went bilobar resections.
Macrovascular invasion and portal and/or hepatic vein
invasion was observed in 27 patients (26.7%). A lymphad-
enectomy of the hepatic hilum up to the retropancreatic
lymph nodes was performed when there was a clinical
suspicion of regional nodal involvement at the time of
hepatectomy. Lymph node metastasis was found by histo-
pathological study for 19 patients (18.8%). A total of 24
patients (23.7%) had concomitant intra- and extrahepatic
disease (lung and/or regional lymph node metastases).
Overall survival and recurrence
Recurrence was observed for 64 patients (63.3%) during
the study follow-up, and the 5-year cumulative risk of
recurrence was 56.7% (Figure 1). The median survival
after recurrence was 24.5 months (range 1 to 41 months)
and the 5-year cumulative overall survival was 31.8%.
The most common site of recurrence was the liver,
which occurred for 32 patients (31.6%). There was recur-
rence at extrahepatic sites for only 19 patients (18.8%)
and at the liver and extrahepatic sites for nine patients
(8.9%) (Table 1, Figure 2).
The prognostic factors analyzed are shown in Table 2.
During transection of the liver parenchyma, when tumors
were exposed on the liver surface there was no association
Table 1 Patterns of recurrence following hepatic
resection of CRCLM (n = 101)
Site of recurrence Recurrences (%)
Overall 64 (63.3%)
Liver only 32 (31.6%)
Liver and extrahepatic 9 (8.9%)
Liver and lungs 5 (4.9%)
Liver and local 2 (1.8%)
Liver and brain 1 (0.9%)
Liver and bone 1 (0.9%)
Extrahepatic only 23 (22.7%)
Lungs 12 (11.8%)
Peritoneal cavity 4 (3.6%)




Table 2 Cox regression of variables associated with





Sex 1.03 (0.34-3.10) 0.7418
Lobectomy 2.99 (0.93-9.60) 0.0967
Portal embolization or ligature 0.46 (0.15-1.38) 0.1672
Simultaneous resection (liver and primary) 1.37 (0.38-4.93) 0.5338
Anatomical versus non-anatomical resection 2.06 (0.83-9.05) 0.1838
Two-stage hepatectomy 2.32 (0.66-7.05) 0.278
Tumor exposed on the liver surface 4.19 (1.31-13.39) 0.2834
Perioperative systemic therapy 0.82 (0.59-2.64) 0.7510
≥4 liver metastasis 2.97 (1.73-8.25) 0.0831
Macroscopic vascular invasion 3.06 (0.85-11.05) 0.0838
Synchronous liver metastases 4.33 (0.28-9.93) 0.0433a
CEA before hepatectomy ≥50 ng/mL 5.51 (1.47-13.83) 0.0024a
Bilobar disease 5.86 (1.95-17.58) 0.0016a
Surgical margins <5 mm 6.32 (1.90-21.01) 0.0026a




Concomitant resectable intra- and
extrahepatic disease
4.81 (1.61-14.37) 0.0042a
Bilobar disease 4.94 (1.65-14.79) 0.0049a
CEA before hepatectomy ≥50 ng/mL 4.13 (0.41-12.08) 0.0192a
Surgical margins <5 mm 1.82 (0.69-4.64) 0.7510
Synchronous liver metastases 1.23 (0.38-3.93) 0.8831
CEA, carcinoembryonic antigen.
aP < 0.05.
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no differences in relapse rates when simultaneous re-
sections of the primary tumor and liver were performed
(P = 0.5338). Perioperative systemic therapy, whether
before and/or after hepatectomy, was not associated with
intra- or extrahepatic recurrence (P = 0.7510). Regarding
the method of hepatectomy (anatomical and/or non-
anatomical) and extent of liver resection (less than or at
least lobectomy), there were no differences in recurrence
rates between these groups (P = 0.1838 and 0.0967,
respectively).
In summary, the univariate analysis selected as predictors
of recurrence: synchronous liver metastases (0.0433), CEA
before hepatectomy ≥50 ng/mL (P = 0.0024), hepatic resec-
tion margins <5 mm (P = 0.0026), intra- and extrahepaticFigure 2 Five-year cumulative overall survival (n = 101).metastases (P = 0.0007), and bilobar disease (P = 0.0016). In
the multivariate analysis, intra- and extrahepatic metastases
(P = 0.0042), bilobar disease (P = 0.0049) and CEA before
hepatectomy ≥50 ng/mL (P = 0.0192) remained significant
predictors.Discussion
Untreated CRCLM have a poor prognosis, with median
survival ranging from 6 to 12 months. Recently, increased
survival after a liver resection has been found in numerous
uncontrolled studies [7,8,13]. These studies showed 5-year
survival ranging from 20% to 58%, and median survival
from 24 to 46 months [4,6-8,10-13,17,18]. However,
several studies have also found that patients have high
recurrence rates, with intrahepatic recurrence being the
most common, occurring for approximately 50% of
cases [4,6,9,19,20]. An occult metastasis of the primary
tumor and residual lesions have been considered as the
two main pathways in which relapse occurs after the
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including liver resection, must be considered according to
the mechanisms of relapse.
Liver surgery is usually considered if the following
conditions are met: (1) curative resection of the primary
tumor is possible, (2) there are only liver metastases, and
(3) clinically, the patient can endure a hepatectomy [23].
However, there is still a lack evidence for the ideal timing,
extent of hepatectomy, resection of extrahepatic metasta-
ses and the best perioperative chemotherapy combination.
The main goal of this study was to evaluate the significant
prognostic factors related to recurrence in patients under-
going a first hepatectomy for CRCLM, aiming at a better
understanding of this complex scenario, and mainly to
help surgeons select patients to undergo liver resection
with reasonable recurrence rates.
The hematogenous dissemination of colorectal cancer
is significantly associated with the size of metastatic liver
tumors according to the metastasis cascade theory [24],
although other studies point to sporadic deviations.
According to this theory, the sequence of metastatic
CRCLM follows a relatively predictable process of
involvement, starting from the liver, then going to the
lung and advancing to other sites. However, this study
did not conclude that the size or number of CRCLM are
significant risk factors for recurrence.
It was found in the univariate analysis of this study
that a surgical margin <5 mm was a risk factor for
recurrence but was not a predictor according to the
multivariate analysis. The role of surgical margin as a
prognostic factor is still a matter of controversy [25-29].
In a large series, it was shown that a margin >1 cm is an
independent predictor of survival [28]. Recently, it was
found that a histological surgical margin ≤5 mm was
associated with a lower disease-free interval and worse
survival rates [29]. In contrast, another study showed that
positive margins were not associated with an increased
risk of relapse [25].
Various devices for coagulation of the liver parenchyma
transection can be potentially detrimental to a surgical
margin evaluation [24,29,30], but in practical terms, hepa-
tectomy should not be contraindicated whatever the
margin thickness, since no other treatment modality alone
is better than resection, even with narrow margins that
range from 0 to 1 cm [28]. In the present study, as already
mentioned, the surgical margin was a prognostic factor
according to the univariate analysis, but not according to
the multivariate analysis.
Although more studies are needed to clarify the clinical
significance of macroscopic vascular invasion, this reflects
the degree of aggressiveness of the tumor and the poten-
tial for intrahepatic micrometastases [29,31], thus it can
be used to estimate the malignant potential. Therefore,
the optimal surgery should include strategies to dealwith macroscopic vein invasion, such as anatomical
liver resection including a Glisson sheath [31].
Another important point is the possibility of performing
simultaneous resections of the liver and the primary site
or of performing resections separated by an interval. No
differences between these two approaches were found in
this study, suggesting that synchronous metastases at
surgery can be resected before the hepatic tumor becomes
inoperable, and without the necessity of compulsory neo-
adjuvant treatment.
Controversy remains whether the actual consensus for
perioperative chemotherapy for resectable or potentially
resectable liver metastases is significantly associated with
disease-free survival or prognosis [32]. The effects of the
combination of surgery and systemic therapy were not
the object of this study, though apparently in the sub-
group of patients with synchronous CRCLM, adjuvant
systemic treatment seems essential. Chemotherapy in
this study relied primarily on 5-FU alone, 5-FU/LV, cap-
ecitabine, FOLFOX, FOLFIRI and bevacizumab. Recently
developed molecular target agents, such as bevacizumab,
have been reported in the literature as strategies that
can improve the prognosis of recurrent and unresectable
colorectal cancer [33-35].
A systematic review by Park et al. [36] concluded that
systemic adjuvant chemotherapy gave a significant im-
provement in disease-free survival, and indicated that
choice for patients with liver metastases from colorectal
cancer after resection in those with a high likelihood of
recurrence. The most suitable systemic chemotherapy
regimen is 5-FU/LV, but many oncologists are using
systemic FOLFOX perioperatively due to the observed
longer disease-free survival. According to Macedo et al.
[37], adjuvant chemotherapy with 5-FU is the most used
regime in clinical practice, with a trend for improvement
of disease-free survival, but with no difference in overall
survival or median disease-progression-free survival. A
retrospective analysis by Boame et al. [38] of 168 patients
of Ottawa Cancer Hospital compared the use of adjuvant,
neoadjuvant and perioperative chemotherapy for patients
with liver metastases from colorectal cancer, and the
conclusion was that regardless of when they received
chemotherapy, these patients had improved overall
survival and disease-free survival.
Currently, the recommended approach for the neoad-
juvant scenario is 2 to 3 months of FOLFOX, but there
are potential negative effects of chemotherapy, such as
the development of extrahepatic lesions and the appear-
ance of postoperative sequelae [37]. The review by Park
et al. [36] also shows that when the conversion of an
unresectable disease is needed, the rates are 15%, 30%
and >50% with the use of FOLFIRI or FOLFOX, regional
hepatic artery infusion of floxuridine, and hepatic artery
infusion with FOLFOX, respectively. In the neoadjuvant
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of 60% and 70%, respectively, have been reported. The
hepatic artery infusion technique was also used by Osawa
et al. [39], with complete response in a patient with
CRCLM after 5-FU infusion for 26 weeks.
Although substantial conclusions for this subject were
not demonstrated in this study, mainly because of the
study design, the use of these new agents may have a
positive impact on the control of relapses by the prob-
able extermination of micrometastases.
Another point of interest is the challenging bilobar liver
metastases. Although some patients in this study did
benefit from aggressive neoadjuvant chemotherapy until
the lesions reduced in size, and then subsequently under-
went a hepatectomy, bilobar disease was an independent
prognostic factor for recurrence in this study. The modal-
ities of increasing resectability in this setting include
radiofrequency ablation [40,41], percutaneous transportal
embolization [42] and hepatectomy in two stages [43].
Ribeiro et al. [44] revealed that CEA levels >200 ng/mL
are associated with poor results. Other studies agree with
this because they cannot demonstrate a clear disadvantage
for survival when there is a high preoperative CEA level.
Torrez [45] points out that favorable survival at 5 years
was observed for patients with a serum CEA level less
than 50 ng/mL, 34.4% versus 18.8% (P ≤ 0.001). In our
study, patients with serum CEA levels above 50 ng/mL
had a poorer prognosis.
The comparative prognosis for CRCLM, either syn-
chronous or metachronous, still remains unclear in the
literature. A systematic review by Tan and Ooi [46]
showed that 14.5% to 24% of patients had synchronous
metastases, and 8.1% to 20% of patients had metachro-
nous metastases. The authors found that survival rates
at 5 and 10 years were 16% to 44% and 20% to 30.9%,
respectively. This study has shown there is a difference
in survival, which favors metachronous lesions, although
statistically significant differences were not always found.
As the review of Tam et al., this study also found a
trend for more favorable prognosis with metachronous
lesions, but this was not confirmed by the multivariate
analysis. Tan and Ooi [46] also reported that despite
not finding differences in survival, there was a shortening
of the disease-free interval after 5 years (18%) for syn-
chronous metastases. Ghirimghelli et al. [47] conducted a
population-based study of 932 patients with metastatic
colon cancer. The 5-year survival for metachronous
metastases was 17.6% while for synchronous metastases it
was 7.2%. Other studies affirm that there are no statisti-
cally significant differences for prognosis and overall sur-
vival between synchronous and metachronous metastases
[48-50].
The criteria for resection of liver metastases have been
recently improved; previously the surgical therapy wasgrounded in how much of the liver was removed. Now-
adays, what remains after resection is what matters.
Characteristics as the number of liver metastases, the size
of the tumors and surgical margins of 1 cm are not static
criteria of unresectability anymore. Currently, lesions
must be removed with negative margins leaving an appro-
priate remnant liver volume. Moreover, patients with
intra- and extrahepatic metastases are now considered as
potential candidates for resection [13]. Angelsen et al. [51]
reported the 5-year survival for patients undergoing a R0
resection as 42.5%, and 16.1% for R1. Park et al. [36] point
out that in the 1980s, only 10% of patients were candi-
dates for resection, and only those with solitary lesions or
with less than four unilobar lesions were eligible. Surgery
is now considered for patients with more extended dis-
ease, and excellent long-term results can be achieved.
Thus, it is estimated that over 50% of patients are poten-
tial candidates for hepatectomy. Concomitant extrahepatic
disease has traditionally been related to a formal contra-
indication for liver resection; however, studies have shown
an increase in overall survival of patients with extrahepatic
disease who underwent hepatectomy and extrahepatic
disease resection with curative intent [44]. For example,
surgery may be beneficial in cases of hepatic pedicle
lymph node involvement (38% survival at 3 years) [52,53].
For lung metastases, resection can be performed safely
with low mortality (0.0% to 2.5%) and overall survival of
24% to 64% at 5 years [44,54,55]. Our results revealed
higher recurrence rates for concomitant resectable extra-
hepatic disease.Conclusions
We can conclude that the currently available treatments
for CRCLM are efficient, but not completely satisfactory,
and the independent risk factors for tumor recurrence
identified in this study can eventually help in making
decisions for this very complex scenario. Because of the
heterogeneity of these patients and variable disease biol-
ogy, more studies are needed to clarify this issue.
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